FBRX vs. SEPN, SOPH, CMPS, BTMD, TNGX, DRUG, CGC, ELDN, ALMS, and BNTC
Should you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Septerna (SEPN), SOPHiA GENETICS (SOPH), COMPASS Pathways (CMPS), biote (BTMD), Tango Therapeutics (TNGX), Bright Minds Biosciences (DRUG), Canopy Growth (CGC), Eledon Pharmaceuticals (ELDN), Alumis (ALMS), and Benitec Biopharma (BNTC). These companies are all part of the "pharmaceutical products" industry.
Forte Biosciences vs.
Septerna (NASDAQ:SEPN) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, community ranking, earnings and risk.
Septerna has higher revenue and earnings than Forte Biosciences.
77.6% of Forte Biosciences shares are held by institutional investors. 3.1% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Septerna presently has a consensus price target of $34.00, indicating a potential upside of 461.06%. Forte Biosciences has a consensus price target of $23.58, indicating a potential upside of 207.07%. Given Septerna's higher possible upside, equities analysts clearly believe Septerna is more favorable than Forte Biosciences.
In the previous week, Septerna had 6 more articles in the media than Forte Biosciences. MarketBeat recorded 9 mentions for Septerna and 3 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.59 beat Septerna's score of 0.62 indicating that Forte Biosciences is being referred to more favorably in the news media.
Septerna's return on equity of 0.00% beat Forte Biosciences' return on equity.
Forte Biosciences received 25 more outperform votes than Septerna when rated by MarketBeat users. However, 83.33% of users gave Septerna an outperform vote while only 61.22% of users gave Forte Biosciences an outperform vote.
Summary
Septerna and Forte Biosciences tied by winning 6 of the 12 factors compared between the two stocks.
Get Forte Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Forte Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:FBRX) was last updated on 3/3/2025 by MarketBeat.com Staff
Free FBRX Stock Alerts